Open AccessLow frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study
Author(s) -
Pankaj M. Shirsat,
Shivani Bansal,
Pooja Prasad,
Rajiv S. Desai
Publication year - 2018
Publication title -
journal of oral and maxillofacial pathology/journal of oral and maxillofacial pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.455
H-Index - 25
eISSN - 1998-393X
pISSN - 0973-029X
DOI - 10.4103/jomfp.jomfp_174_17
Subject(s) - ameloblastoma , immunohistochemistry , pathology , medicine , v600e , population , maxilla , biology , dentistry , mutation , biochemistry , environmental health , gene
Ameloblastoma is an uncommon, benign neoplasm of odontogenic epithelium commonly affecting the posterior mandible (almost 80%) particularly in the molar/ramus region, with occasional tumors involving the maxilla. Recently, there has been much interest generated after the reports of BRAF V600E mutations in ameloblastomas with a frequency of 46%-80% using both molecular as well as immunohistochemical (IHC) techniques. We sought to assess the presence of BRAF V600E expression in ameloblastomas in Indian patients and correlate the same with clinical behavior and histological variants by performing IHC analysis with anti-BRAF V600E antibody.